Report suggests those at high risk for the disease should be periodically revaccinated
MONDAY, Sept. 28 (HealthDay News) -- One dose of the quadrivalent meningococcal conjugate vaccine may not be enough to confer ongoing protection, and vaccination should be repeated in those at high risk, according to a study in the Sept. 25 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.
The Advisory Committee on Immunization Practices recommends the meningococcal disease vaccine, manufactured by Sanofi Pasteur of Swiftwater, Pa., to be given to all children aged 11 to 18 years and to people aged 2 to 55 years who are at increased risk for the disease.
However, people with persistent complement component deficiencies, anatomic or functional asplenia, and those at higher than normal risk of exposure either through travel to areas where the disease in endemic or through laboratory exposure, should be revaccinated, the researchers recommend. Those who received the vaccine at age 7 years and above should be vaccinated every five years, while the recommended interval for those vaccinated between 2 and 6 years of age is three years.
"This report provides the rationale for the new recommendations and updates and replaces previous recommendations for revaccination with quadrivalent meningococcal conjugate vaccine," the authors write.